Akari Therapeutics (NASDAQ: AKTX) reported a widened net loss for the second quarter of 2026, reflecting increased investment in its lead antibody drug conjugate (ADC) candidate, AKTX-101. The Tampa-based oncology biotechnology company posted a net loss of $4.8 million for the three months ended June 30, 2026, compared to a net loss of $1.9 million in the second quarter of 2025.

The expansion in the deficit was primarily driven by higher research and development (R&D) expenses, which rose to $2.1 million from $0.7 million a year earlier. This increase supports IND-enabling activities and manufacturing work required to initiate Phase 1 clinical trials for AKTX-101, which are planned for mid-2027. General and administrative (G&A) expenses remained stable at $2.5 million, unchanged from the prior-year period.

Financial Position and Capital Raise

Despite the operating losses, Akari strengthened its balance sheet during the quarter through strategic financing. The company secured approximately $8.6 million in gross proceeds, comprising $5.5 million from a private placement and $3.1 million from warrant exercises. After costs, the company received approximately $8.0 million in net proceeds.

As of June 30, 2026, cash totaled $7.7 million, an increase from $5.2 million as of December 31, 2025. The infusion of capital, led by long-term strategic investors, is intended to support the continued advancement of AKTX-101 towards the clinic and expand the company’s ADC payload platform.

*Cash as of December 31, 2025.

What the Numbers Show

The financial data highlights a clear shift in capital allocation towards clinical readiness. R&D expenses tripled year-over-year, accounting for roughly 44% of the total quarterly burn rate ($4.8 million net loss + non-cash items implied by expense structure, though strictly based on disclosed expenses: $2.1M R&D + $2.5M G&A = $4.6M total expenses vs $4.8M net loss). The significant increase in R&D spending directly correlates with the company’s timeline to initiate Phase 1 trials in mid-2027, indicating that near-term losses will likely remain elevated as manufacturing and regulatory preparations accelerate. Meanwhile, the successful raise of $8.6 million provides a critical buffer, extending the runway for these preclinical-to-clinical transition activities.

Pipeline and Strategic Updates

Beyond financial results, Akari highlighted progress in its scientific platform:

• AKTX-101 Advancement: The company continues IND-enabling activities for its lead candidate, which targets the Trop2 receptor using a novel PH1 spliceosome-modulating payload. Preclinical data presented at ASCO 2026 demonstrated synergistic anti-tumor activity when PH1 was combined with a KRAS inhibitor in pancreatic cancer models.
• Whitehawk Collaboration: Akari entered a research collaboration with Whitehawk Therapeutics to explore dual-payload ADCs. This partnership combines Akari’s PH1 payload with Whitehawk’s topoisomerase I payload platform to investigate synergistic anti-tumor effects.
• Intellectual Property: The company expanded its IP portfolio with newly issued international patents for its PH1 technology, strengthening long-term protection for its platform.

New Preclinical Data in Urothelial Cancer

Akari announced new preclinical data demonstrating the potential of AKTX-101 as a differentiated therapeutic approach for urothelial cancer in disease settings where currently available ADC therapies may have limited clinical benefit. The findings showed meaningful anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models, including advanced urothelial cancer with limited response to currently approved ADC therapy and tumors with acquired resistance following treatment with a first-generation TROP2-directed ADC.

The data provide additional validation for Akari’s strategy of developing ADCs with a differentiated payload mechanism designed to address emerging limitations associated with existing ADC payload classes, such as microtubule and topoisomerase 1 inhibitors. Urothelial cancer has become one of the fastest-growing categories for ADC therapy, with Padcev representing greater than $3.5 billion in annual sales. However, patients that relapse after receiving Padcev continue to face significant unmet medical needs.

Key findings from the recent preclinical studies include:

• Activity in Advanced Models: AKTX-101 demonstrated statistically significant anti-tumor activity in the UM-UC-14 advanced urothelial carcinoma model, which represents metastatic urothelial cancer where Padcev is currently approved as first-line therapy. While Padcev had limited responsiveness in this model, AKTX-101 achieved statistically significant tumor growth inhibition compared with vehicle.
• Overcoming Resistance: The candidate demonstrated encouraging activity following acquired resistance to the first-generation TROP2-directed ADC Trodelvy. Tumors initially treated with Trodelvy developed resistance and resumed growth. When switched to AKTX-101, tumor growth was again slowed, suggesting that resistance was associated with the Topoisomerase I payload rather than loss of the TROP2 target itself.

Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, stated that as ADCs move earlier in the treatment paradigm, more patients will require additional treatment following relapse. He noted that the new preclinical findings strengthen confidence in AKTX-101 as the program advances toward Phase 1 development.

Satyajit Mitra, Ph.D., Head of Oncology R&D at Akari Therapeutics, added that the activity observed in tumors resistant to Trodelvy suggests resistance may be driven by the payload. These findings support the hypothesis that introducing a differentiated payload mechanism may overcome payload-specific resistance while preserving target tumor engagement.

Akari Therapeutics announced a strategic research collaboration with Whitehawk Therapeutics to expand the potential application of its PH1 platform into dual-payload antibody-drug conjugates (ADCs). The agreement focuses on evaluating Akari's proprietary PH1 spliceosome modulating payload in combination with Whitehawk's topoisomerase I payload technology.

The collaboration is designed to investigate the potential of combining these complementary ADC payload technologies. The companies aim to synergize and enhance anti-tumor activity through this dual-payload approach.

Strategic Implications

This partnership expands Akari's strategic position in novel ADC payloads. The move demonstrates continued strong interest in ADC payload innovation across the biotech and pharmaceutical sectors.

The collaboration highlights the unique potential of the PH1 payload by testing it alongside another established mechanism of action. By combining spliceosome modulation with topoisomerase I inhibition, the research seeks to identify synergistic effects that may improve therapeutic outcomes compared to single-payload approaches.